GLT2 inhibitors early following an acute MI to reduce cardiovascular mortality and morbidity.



Sodium glucose cotransporter-2 (SGLT2) inhibitors improve cardiorenal outcomes in patients with type 2 diabetes mellitus (T2DM), chronic kidney disease (CKD), and chronic heart failure with reduced ejection fraction (HFrEF).

Copyright © 2020 Terumo India Private limited

X
Important information regarding

By using this website, you consent to the use of cookies in accordance with our